Literature DB >> 12183253

In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.

Catherine Clark1, Bülent Bozdogan, Mihaela Peric, Bonifacio Dewasse, Michael R Jacobs, Peter C Appelbaum.   

Abstract

Abilities of amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin to select resistant mutants of Haemophilus influenzae were tested by multistep and single-step methodologies. For multistep studies, 10 random strains were tested: 5 of these were beta-lactamase positive. After 50 daily subcultures in amoxicillin-clavulanate, MICs did not increase more than fourfold. However, cefprozil MICs increased eightfold for one strain. Clarithromycin and azithromycin gave a >4-fold increase in 8 and 10 strains after 14 to 46 and 20 to 50 days, respectively. Mutants selected by clarithromycin and azithromycin were associated with mutations in 23S rRNA and ribosomal proteins L4 and L22. Three mutants selected by clarithromycin or azithromycin had alterations in ribosomal protein L4, while five had alterations in ribosomal protein L22. Two mutants selected by azithromycin had mutations in the gene encoding 23S rRNA: one at position 2058 and the other at position 2059 (Escherichia coli numbering), with replacement of A by G. One clone selected by clarithromycin became hypersusceptible to macrolides. In single-step studies azithromycin and clarithromycin had the highest mutation rates, while amoxicillin-clavulanate had the lowest. All resistant clones were identical to parents as observed by pulsed-field gel electrophoresis. The MICs of azithromycin for azithromycin-resistant clones were 16 to >128 micro g/ml, and those of clarithromycin for clarithromycin-resistant clones were 32 to >128 micro g/ml in multistep studies. For strains selected by azithromycin, the MICs of clarithromycin were high and vice versa. After 50 daily subcultures in the presence of drugs, MICs of amoxicillin-clavulanate and cefpodoxime against H. influenzae did not rise more than fourfold, in contrast to cefprozil, azithromycin, and clarithromycin, whose MICs rose to variable degrees.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183253      PMCID: PMC127454          DOI: 10.1128/AAC.46.9.2956-2962.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  The hidden impact of antibacterial resistance in respiratory tract infection. Re-evaluating current antibiotic therapy.

Authors:  W A Craig
Journal:  Respir Med       Date:  2001-06       Impact factor: 3.415

Review 3.  Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.

Authors:  M R Jacobs
Journal:  Clin Microbiol Infect       Date:  2001-11       Impact factor: 8.067

4.  Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae.

Authors:  K Ubukata; Y Shibasaki; K Yamamoto; N Chiba; K Hasegawa; Y Takeuchi; K Sunakawa; M Inoue; M Konno
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae.

Authors:  T A Davies; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

6.  Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

Authors:  Annie Canu; Brigitte Malbruny; Maëlle Coquemont; Todd A Davies; Peter C Appelbaum; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

7.  In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae.

Authors:  K Nagai; T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 8.  Haemophilus influenzae: antibiotic susceptibility.

Authors:  C A Needham
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

9.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

10.  Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.

Authors:  A Tait-Kamradt; T Davies; P C Appelbaum; F Depardieu; P Courvalin; J Petitpas; L Wondrack; A Walker; M R Jacobs; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

View more
  18 in total

1.  Chemistry and biology of macrolide antiparasitic agents.

Authors:  Younjoo Lee; Jun Yong Choi; Hong Fu; Colin Harvey; Sandeep Ravindran; William R Roush; John C Boothroyd; Chaitan Khosla
Journal:  J Med Chem       Date:  2011-03-23       Impact factor: 7.446

2.  Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  Tatiana Bogdanovich; Catherine Clark; Lois Ednie; Gengrong Lin; Kathy Smith; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Activity of LBM415 compared to those of 11 other agents against Haemophilus species.

Authors:  Tatiana Bogdanovich; Kathy A Smith; Catherine Clark; Glenn A Pankuch; Gengrong Lin; Pamela McGhee; Bonifacio Dewasse; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Ribosomal Mutations Conferring Macrolide Resistance in Legionella pneumophila.

Authors:  Ghislaine Descours; Christophe Ginevra; Nathalie Jacotin; Françoise Forey; Joëlle Chastang; Elisabeth Kay; Jerome Etienne; Gérard Lina; Patricia Doublet; Sophie Jarraud
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

5.  Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae.

Authors:  Klaudia Kosowska; Kim Credito; Glenn A Pankuch; Dianne Hoellman; Gengrong Lin; Catherine Clark; Bonifacio Dewasse; Pamela McGhee; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan.

Authors:  Shoji Seyama; Takeaki Wajima; Hidemasa Nakaminami; Norihisa Noguchi
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 7.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

8.  In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance.

Authors:  Olusegun O Soge; Stephen J Salipante; David No; Erin Duffy; Marilyn C Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

9.  Haemophilus influenzae bla(ROB-1) mutations in hypermutagenic deltaampC Escherichia coli conferring resistance to cefotaxime and beta-lactamase inhibitors and increased susceptibility to cefaclor.

Authors:  Juan-Carlos Galán; María-Isabel Morosini; María-Rosario Baquero; Milagro Reig; Fernando Baquero
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Revisiting the mechanism of macrolide-antibiotic resistance mediated by ribosomal protein L22.

Authors:  Sean D Moore; Robert T Sauer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.